Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Fennec Pharmaceuticals Ord Shs T.FRX

Alternate Symbol(s):  FENC

Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is a Food and Drug Administration approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase 3 clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.


TSX:FRX - Post by User

Post by IBTryinIton Dec 20, 2010 1:23pm
228 Views
Post# 17871291

Sorry

SorryHere are the NR's as released by the company  

October 14, 2010

GAP-107B8 showed no signs of toxicity in rats using continuous infusion intravenous administration (other than minimal local tissue irritation at the site of the injection in the highest dose groups) at dose levels greater than dose ranges previously shown to be effective in reducing tumour burden in mice using bolus intravenous

The stock never moved

PharmaGap Completes Conversion of NRC Debt to Shares

November 4, 2010

Despatate attempt to raise funds

PharmaGap Completes Private Placement of Equity Units

November 19, 2010

A total of 3,931,268 units were issued at a price of
.1455 per Unit. Each Unit consists of one common share and one warrant to purchase a common share at an exercise price of
.25 per share for the first two years and
.35 per share for the third year of the three year warrant term. The closing of this private placement is subject to the approval of the TSX Venture Exchange and the shares and warrants issued pursuant to the private placement are restricted from trading for four months from the date of closing.

Another desparate attempt to raise much needed funds

CORRECTION FROM SOURCE: PharmaGap Completes Private Placement of Equity Units

November 19, 2010

announced today that it has completed a private offering of equity units (the "Units") in the amount of $572,000. A total of 4,085,714 units were issued at a price of
.14 per Unit. Each Unit consists of one common share and one warrant to purchase a common share at an exercise price of
.25 per share for the first two years and
.35 per share for the third year of the three year warrant term. The closing of this private placement is subject to the approval of the TSX Venture Exchange and the shares and warrants issued pursuant to the private placement are restricted from trading for four months from the date of closing. The press release issued earlier today stated an incorrect issue price and number of units.

Same news as before only rereleased

This company is in trouble and is in need of funding so please donate

JMHO that I thought I should share. I have seen this pattern before and it did not end well

Bullboard Posts